Shaperon

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1, IL-18, IL-6, and TNF-, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimers disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer...

Nanobody,damps,oncology,inflammation,tgr5,atopy,sepsis,alzheimer,ulcerative colitis,stomach cancer,colon cancer,immune,인플라마좀,아토피 피부염,항염증제,나노바디,알츠하이머,코로나19치료제,면역학,항체치료제,패혈증,염증복합체 억제제,immunology,면역항암제,and 항암

Shaperon operates in the Biotechnology research industry.

Shaperon's revenue is < 1m

Shaperon has 11 - 50 employees.